Hydroxybenazamide compounds for treatment of cancer

• US 20060025485A1
• Filed: 06/29/2005
• Published: 02/02/2006
• Est. Priority Date: 07/01/2004
• Status: Abandoned Application

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: Chen, Herbert, Van Gompel, Jamie J., Holen, Kyle
• Application Number:
  US11/169,512
• Publication Number:
  US 20060025485A1
• Time in Patent Office: Days
• US Class Current: 514/616
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/167 having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia

Abstract

The present invention provides for the treatment of cancers, particularly neuroendocrine cancers, using the Raf-1 inducer ZM336372, or analogs thereof.

Claims

1. A method of inhibiting growth of a cancer cell comprising an intact raf signaling pathway comprising contacting said cell with an effective amount of a compound having the structure:

or a prodrug or an analog thereof.

2. The method of claim 1, wherein contacting comprises providing said compound or an analog thereof to said cell.

3. The method of claim 1, wherein contacting comprises providing a prodrug to said cell that is converted in situ to said compound or an analog thereof.

4. The method of claim 1, wherein said cancer cell is a neuroendocrine cancer cell, a colon cancer cell, a pancreatic cancer cell, a hepatocellular cancer cell, a glioma cell, a carcinoid cancer cell, or a medullary thyroid cancer cell.

11. The method of claim 1, wherein said compound is:

12. The method of claim 1, wherein an effective amount comprises about 200 mg to about 3 grams per day.

13. The method of claim 1, wherein an effective amount comprises about 0.0067 mg/kg to about 66.7 mg/kg per day.

14. The method of claim 1, further comprising contacting said cell with a second agent.

15. The method of claim 14, wherein said second agent is radiation, a chemotherapeutic, or a biological anti-cancer agent.

5-10. -10. (canceled)

16-18. -18. (canceled)

19. A method of treating a cancer in a subject, cells of said cancer comprising an intact raf signaling pathway, comprising contacting said subject with an effective amount of a compound having the structure:

or a prodrug or an analog thereof.

20-36. -36. (canceled)

37. A method of inhibiting growth of a cancer cell comprising an intact p21 signaling pathway comprising contacting said cell with an effective amount of a compound having the structure:

or a prodrug or an analog thereof.

38. A method of treating a cancer in a subject, cells of said cancer comprising an intact p21 signaling pathway, comprising contacting said subject with an effective amount of a compound having the structure:

or a prodrug or an analog thereof.

39. (canceled)

46. The method of claim 39, wherein said glioma is a clinically aggressive glioma.

40. A method of treating a neuroendocrine cancer in a subject comprising contacting said subject with an effective amount of a compound having the structure:

or a prodrug or an analog thereof.

41. (canceled)

42. A method of treating a carcinoid cancer in a subject comprising contacting said subject with an effective amount of a compound having the structure:

or a prodrug or an analog thereof.

43-44. -44. (canceled)

45. A method of treating a glioma cancer in a subject comprising contacting said subject with an effective amount of a compound having the structure:

or a prodrug or an analog thereof.

47. A method of screening a candidate substance for activity against carcinoid cancer cells comprising:

(a) providing a cell having an intact raf signaling pathway;

(b) contacting said cell with candidate substance; and

(c) assessing the effect of said candidate substance on the raf signaling pathway,

wherein an increase in raf pathway signaling activity, as compared to that observed in the absence of said candidate substance, indicates that said candidate substance is active against carcinoid cancer cells.

48-51. -51. (canceled)

52. A method of reducing chromogranin levels in neuroendocrine cancer cell comprising contacting said subject with an effective amount of a compound having the structure:

or a prodrug or an analog thereof.

53-56. -56. (canceled)